EUVIMEDEUVIMED entdecken
Open Access

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients

Sha Zhu, Nanwei Xu, Jiayu Liang, Fengnian Zhao, Zilin Wang, Yuchao Ni, Jindong Dai, Jinge Zhao, Xingming Zhang, Junru Chen, Guangxi Sun, Pengfei Shen und 1 weitere

Oncology Research · 2023

DOI: 10.32604/or.2023.028321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2023. Verfasst von Sha Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

KMT2 (lysine methyltransferase) family enzymes are epigenetic regulators that activate gene transcription. KMT2C is mainly involved in enhancer-associated H3K4me1, and is also one of the top mutated genes in cancer (6.6% in pan-cancer). Currently, the clinical significance of KMT2C mutations in prostate cancer is understudied.

Methods

We included 221 prostate cancer patients diagnosed between 2014 and 2021 in West China Hospital of Sichuan University with cell-free DNA-based liquid biopsy test results in this study. We investigated the association between KMT2C mutations, other mutations, and pathways. Furthermore, we evaluated the prognostic value of KMT2C mutations, measured by overall survival (OS) and castration resistance-free survival (CRFS). Also, we explored the prognostic value of KMT2C mutations in different patient subgroups. Lastly, we investigated the predictive value of KMT2C mutations in individuals receiving conventional combined anti-androgen blockade (CAB) and abiraterone (ABI) as measured by PSA progression-free survival (PSA-PFS).

Results

The KMT2C mutation rate in this cohort is 7.24% (16/221). KMT2C-mutated patients showed worse survival than KMT2C-wild type (WT) patients regarding both CRFS and OS (CRFS: mutated: 9.9 vs. WT: 22.0 months, p = 0.015; OS: mutated: 71.9 vs. WT 137.4 months, p = 0.012). KMT2C mutations were also an independent risk factor in OS [hazard ratio: 3.815 (1.461, 9.96), p = 0.006] in multivariate analyses. Additionally, we explored the association of KMT2C mutations with other genes. This showed that KMT2C mutations were associated with Serine/Threonine-Protein Kinase 11 (STK11, p = 0.004) and Catenin Beta 1 (CTNNB1, p = 0.008) mutations. In the CAB treatment, KMT2C-mutated patients had a significantly shorter PSA-PFS compared to KMT2C-WT patients. (PSA-PFS: mutated: 9.9 vs. WT: 17.6 months, p = 0.014). Moreover, KMT2C mutations could effectively predict shorter PSA-PFS in 10 out of 23 subgroups and exhibited a strong trend in the remaining subgroups.

Conclusions

KMT2C-mutated patients showed worse survival compared to KMT2C-WT patients in terms of both CRFS and OS, and KMT2C mutations were associated with STK11 and CTNNB1 mutations. Furthermore, KMT2C mutations indicated rapid progression during CAB therapy and could serve as a potential biomarker to predict therapeutic response in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantHumansMaleEpigenesis, GeneticLiquid BiopsyMutationTreatment OutcomeDNA-Binding Proteins

Stichwörter der Autor:innen

BiomarkerEpigenetic regulatorKMT2CLiquid biopsyProstate cancerSurvival

Substanzen

Prostate-Specific AntigenKMT2C protein, humanDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.

Zitieren

APA

Zhu, S., Xu, N., Liang, J., Zhao, F., Wang, Z., Ni, Y., Dai, J., Zhao, J., Zhang, X., Chen, J., Sun, G., Shen, P., & Zeng, H. (2023). Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients. Oncology Research. https://doi.org/10.32604/or.2023.028321

Vancouver

Zhu S, Xu N, Liang J, Zhao F, Wang Z, Ni Y, et al. Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients. Oncology Research. 2023. doi:10.32604/or.2023.028321

BibTeX
@article{Zhu2023,
  author = {Zhu, Sha and Xu, Nanwei and Liang, Jiayu and Zhao, Fengnian and Wang, Zilin and Ni, Yuchao and Dai, Jindong and Zhao, Jinge and Zhang, Xingming and Chen, Junru and Sun, Guangxi and Shen, Pengfei and Zeng, Hao},
  title = {Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients},
  journal = {Oncology Research},
  year = {2023},
  doi = {10.32604/or.2023.028321}
}
Kostenlos starten →